-
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
25 Apr 2024 05:00 GMT
… of 2026. PRELIMINARY UNAUDITED 2023 FINANCIAL RESULTS & FINANCING
Revenue from contracts … or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain …
-
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
28 Feb 2024 23:03 GMT
… (Nasdaq: CPRX) today reported financial results for the fourth quarter and … and Full Year 2023 Financial Results Total revenues: Total revenues … milestone payment made to Santhera upon the approval of … ET to discuss the financial results and provide a business …
-
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update
07 Sep 2023 05:00 GMT
… – Santhera Pharmaceuticals (SIX: SANN) announces the Company’s financial results for the … USA 117:24285-24293 About Santhera
Santhera Pharmaceuticals (SIX: SANN) … or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain …
-
Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
09 Aug 2023 20:17 GMT
… Nasdaq: CPRX) today reported financial results for the second quarter of … Duchenne muscular dystrophy, from Santhera Pharmaceuticals, with a PDUFA … in key areas.
Financial Results for Second Quarter 2023 … ET to discuss the financial results and provide a …
-
Santhera Announces Half-Year 2022 Financial Results and Provides Corporate Update
31 Oct 2022 06:00 GMT
… discuss the 2022 half-year financial results and comment on ongoing corporate … or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain …
-
Catalyst Pharma acquires exclusive North American license for vamorolone for DMD from Santhera Pharma
20 Jul 2023 10:48 GMT
… its acquisition from Santhera Pharmaceuticals Holdings (Santhera) of an … Europe and Japan should Santhera pursue partnership opportunities. … approximately 11.26% of Santhera's outstanding … s second-quarter 2023 financial results conference call, which is …
-
Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
19 Jul 2023 10:00 GMT
… from Santhera Pharmaceuticals Holdings ("Santhera") … and Japan should Santhera pursue partnership opportunities. … second-quarter 2023 financial results conference call, which … whether Catalyst and Santhera will successfully develop additional …
-
Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October
29 Sep 2022 07:25 GMT
… , September 29, 2022 – Santhera Pharmaceuticals SANN publishes preliminary financial results for the half … or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain …
-
Santhera Announces Preliminary 2022 Half-year Financial Results Ahead of Full Report Publication by End of October
29 Sep 2022 05:00 GMT
… 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) publishes preliminary financial results for the half … or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain …
-
Santhera Announces Preliminary Unaudited 2022 Annual Results Ahead of Full Report Publication by End of May and Provides Corporate Update
27 Apr 2023 06:53 GMT
… commercialization plans.
PRELIMINARY UNAUDITED 2022 FINANCIAL RESULTS & FINANCING
Revenue from contracts … or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain …